These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8963000)

  • 1. [Presence of excipients in pharmaceutical products in 3 sources of therapeutic information].
    Altimiras J; Nieto-Hernández T; Buitrago F
    Aten Primaria; 1996 Sep; 18(4):190-3. PubMed ID: 8963000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reliability of 3 sources of information about medication excipients].
    Buitrago F; Altimiras J; Nieto-Hernández T
    Aten Primaria; 1996 Nov; 18(9):480-3. PubMed ID: 9280442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Trust of primary care physicians in the reliability of the vade mecum].
    Nieto-Hernández T; Altimiras J; Buitrago F
    Aten Primaria; 1996 Mar; 17(4):247-50. PubMed ID: 8679858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
    James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
    Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excipients in medicinal products used in gastroenterology as a possible cause of side effects.
    Ursino MG; Poluzzi E; Caramella C; De Ponti F
    Regul Toxicol Pharmacol; 2011 Jun; 60(1):93-105. PubMed ID: 21354240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹³C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations, Part I: Chemical shifts assignment.
    Pisklak DM; Zielińska-Pisklak MA; Szeleszczuk Ł; Wawer I
    J Pharm Biomed Anal; 2016 Apr; 122():81-9. PubMed ID: 26845204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Notes on Impact of Excipients on Drug Products and the Maillard Reaction.
    Chowdhury DK; Sarker H; Schwartz P
    AAPS PharmSciTech; 2018 Feb; 19(2):965-969. PubMed ID: 28948567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unclear on dose adjustment in renal impairment].
    Asker-Hagelberg C; Rydberg D; Hentschke M; Holm L; Rosenborg S; Elinder CG
    Lakartidningen; 2013 May 22-28; 110(21):1030-2. PubMed ID: 23805768
    [No Abstract]   [Full Text] [Related]  

  • 9. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine.
    Wirth DD; Baertschi SW; Johnson RA; Maple SR; Miller MS; Hallenbeck DK; Gregg SM
    J Pharm Sci; 1998 Jan; 87(1):31-9. PubMed ID: 9452965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in the α and β anomer content of commercially available lactose.
    Altamimi MJ; Wolff K; Nokhodchi A; Martin GP; Royall PG
    Int J Pharm; 2019 Jan; 555():237-249. PubMed ID: 30395957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility study between acetylcysteine and some commonly used tablet excipients.
    Kerc J; Srcic S; Urleb U; Kanalec A; Kofler B; Smid-Korbar J
    J Pharm Pharmacol; 1992 Jun; 44(6):515-8. PubMed ID: 1359077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative and quantitative control of pediatric syrups using Nuclear Magnetic Resonance and chemometrics.
    Alves Filho EG; Silva LMA; Araújo NVP; Alves EG; Lião LM; Alcantara GB
    J Pharm Biomed Anal; 2018 May; 153():29-36. PubMed ID: 29459233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
    Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
    J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing quantitative certificate of analysis data to assess the amount of excipient lot-to-lot variability sampled during drug product development.
    Kushner J
    Pharm Dev Technol; 2013; 18(2):333-42. PubMed ID: 21877870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical excipients and the information on drug labels.
    Balbani AP; Stelzer LB; Montovani JC
    Braz J Otorhinolaryngol; 2006; 72(3):400-6. PubMed ID: 17119779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of some hydrophilic excipients on the rate of gabapentin and baclofen lactamization in lyophilized formulations.
    Cutrignelli A; Denora N; Lopedota A; Trapani A; Laquintana V; Latrofa A; Trapani G; Liso G
    Int J Pharm; 2007 Mar; 332(1-2):98-106. PubMed ID: 17071027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From single excipients to dual excipient platforms in dry powder inhaler products.
    Shur J; Price R; Lewis D; Young PM; Woollam G; Singh D; Edge S
    Int J Pharm; 2016 Dec; 514(2):374-383. PubMed ID: 27262269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical design of a new lactose-free coprocessed excipient: application of hydrochlorothiazide as a low solubility drug model.
    Viscasillas Clerch A; Fernandez Campos F; Del Pozo A; Calpena Campmany AC
    Drug Dev Ind Pharm; 2013 Jul; 39(7):961-9. PubMed ID: 22607083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.